MRI ALLOWS RESEARCHERS TO SEE BENEATH THE SURFACE

therapies approved by Health Canada for people living with the most common form of the disease, relapsing-remitting MS (RRMS).

“Imaging has been that last piece that has really allowed researchers and regulators to see underneath the surface,” says Asis. “Researchers can say with confidence that following treatment with a particular drug, they are seeing less inflammation in the brain, and fewer lesions.”

In her role with the MS Society of Canada, Asis has observed the accelerated pace of clinical tests and drug approvals, and is encouraged by the progress. Today those afflicted with MS have more options available to minimize attacks, and slow the progression of the disease. And more new and promising therapies are in the pipeline.

“It allows for people with MS to have a choice in treatments based on what suits them,” Asis notes. While some people are fine with injectable medications, others shy away from needles. There are a number of oral medications approved in Canada, and new infusion treatments that greatly reduce the impact on patient lifestyle, with longer periods possible between treatments. “There are a lot of different choices in terms of treatment, and that speaks to the progress in research that we have seen.”

While people with RRMS have more options, those living with more severe forms of the disease are still hoping for a breakthrough. This past March, the first drug to treat adult patients with primary progressive multiple sclerosis (PPMS) was approved in the United States. There is reason to anticipate new therapies in the coming years to lessen the burden of a disease that for so many decades confounded researchers and doctors.